Summary of PRO reporting in chemotherapy-based trials with or without immunotherapy for LA-NPC
| Study (identifier) | Sample size* | Stage | Study design | Interventional regimens | PRO scales |
|---|---|---|---|---|---|
| Liu et al.1 (NCT03700476) | 357 | III–IVA, except T3–4N0 and T3N1 (AJCC 8th) | Multicenter, phase 3, RCT | GP IC + CCRT + sintilimab (induction, concurrent, and adjuvant) | EORTC QLQ-C30 |
| Liang et al.2 (NCT03427827) | 334 | T4N1M0/T1–4N2–3M0 (AJCC 8th) | Multicenter, phase 3, RCT | GP IC + CCRT + adjuvant camrelizumab | EORTC QLQ-C30 |
| Liu et al.3 (NCT03925090) | 87 | III–IVA (AJCC 8th) | single-center, phase 2, RCT | CCRT + toripalimab (induction and adjuvant) | EORTC QLQ-C30, EORTC QLQ-H&N35 |
| Xu et al.4 (NCT04907370) | 532 | T4N1M0/T1–4N2–3M0 (AJCC 8th) | Multicenter, phase 3, RCT | GP IC + IMRT + toripalimab (induction, concurrent, and adjuvant) | PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-H&N35, FACT-G, FACT-H&N |
| Xu et al.5 (NCT03984357) | 152 | T4N1M0/T1–4N2–3M0 (AJCC 8th) | Multicenter, phase 2, single-arm | GP IC + IMRT + nivolumab (induction, concurrent, and adjuvant) | PRO-CTCAE, EORTC QLQ-C30, EORTC QLQ-H&N35, FACT-G, FACT-H&N |
| You et al.6 (NCT04453826) | 572 | T4NxM0/TxN3M0 (AJCC 8th) | Multicenter, phase 3, RCT | GP IC + CCRT + camrelizumab (concurrent and adjuvant) | EORTC QLQ-C30 |
| Lv et al.7 (NCT04072107) | 306 | III–IVA (AJCC 8th) | Multicenter, phase 2 | ctEBV DNA-guided risk-adapted therapy | EORTC QLQ-C30 |
| Chen et al.16 (NCT02958111) | 335 | III–IVA, except T3–4N0 and T3N1 (AJCC 8th) | Multicenter, phase 3, RCT | Definitive chemoradiotherapy + adjuvant metronomic capecitabine | EORTC QLQ-C30 |
| Tang et al.17 (NCT01540136) | 145 | T1–4N1–3M0/T3–4N0M0 (AJCC 7th) | Two centers, phase 3, RCT | IMRT + concurrent nedaplatin | EORTC QLQ-C30, QLQ-H&N35 |
PRO, patient-reported outcome; LA-NPC, locoregionally advanced nasopharyngeal carcinoma; GP, gemcitabine-cisplatin; IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; IMRT, intensity-modulated radiotherapy; MRLN, medial retropharyngeal lymph node; ctEBV, circulating tumor Epstein-Barr; AJCC, American Joint Committee on Cancer; RCT, randomized controlled trial; CTCAE, Common Terminology Criteria for Adverse Events; EORTC, European Organisation for Research and Treatment of Cancer; QLQ-C30, quality-of-life questionnaire core-30; QLQ-H&N35, quality-of-life questionnaire head-and-neck-35; FACT-G, Functional Assessment of Cancer Therapy-General; FACT-H&N, Functional Assessment of Cancer Therapy-Head and Neck. *Recorded sample size is the maximum number of respondents across the different PRO questionnaires.